MentionFox
Home › Stakes › Eloxx Pharmaceuticals, Inc.
5%+ stakes · Schedule 13D and 13G

Eloxx Pharmaceuticals, Inc.: 5%+ holders

Who has reported owning 5% or more of Eloxx Pharmaceuticals, Inc., from Schedule 13D and 13G filings: each holder's stake as filed, the timeline, and the purpose each 13D states, quoted.

At 5% or more8
Filings12
Latest filing2026-08-14

Eloxx Pharmaceuticals, Inc. has 12 Schedule 13D or 13G filings on record since 2026-05-01. 8 holders' latest filing reports 5% or more of common stock, $0.01 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

HolderPercentSharesLatestEvent date
Domicilium Capital Partners LLC19.99%854,973SCHEDULE 13G, 2026-06-172026-06-05
Coastlands Capital LP9.99%410,530SCHEDULE 13G, 2026-06-172026-06-10
Raymond Debbane9.99%403,586SCHEDULE 13G, 2026-06-152026-06-09
Aberdeen Group plc9.91%400,000SCHEDULE 13G, 2026-07-272026-06-30
Nantahala Capital Management, LLC9.91%400,000SCHEDULE 13G, 2026-08-142026-06-30
EcoR1 Capital, LLC9.9%403,586SCHEDULE 13G, 2026-06-162026-06-09
Stonepine Capital Management, LLC9.9%403,228SCHEDULE 13G, 2026-06-162026-06-09
Srinivas Akkaraju9.9%403,586SCHEDULE 13G, 2026-08-142026-06-10

Timeline

FiledHolderPercentFiling
2026-05-01Coastlands Capital LP16.51%SCHEDULE 13G
2026-05-04Domicilium Capital Partners LLC18.6%SCHEDULE 13G
2026-05-29Coastlands Capital LP4.99%SCHEDULE 13G/A
2026-06-05Domicilium Capital Partners LLC4.9%SCHEDULE 13G/A
2026-06-15Raymond Debbane9.99%SCHEDULE 13G
2026-06-16EcoR1 Capital, LLC9.9%SCHEDULE 13G
2026-06-16Stonepine Capital Management, LLC9.9%SCHEDULE 13G
2026-06-17Domicilium Capital Partners LLC19.99%SCHEDULE 13G
2026-06-17Coastlands Capital LP9.99%SCHEDULE 13G
2026-07-27Aberdeen Group plc9.91%SCHEDULE 13G
2026-08-14Nantahala Capital Management, LLC9.91%SCHEDULE 13G
2026-08-14Srinivas Akkaraju9.9%SCHEDULE 13G
RSS

Tools for this story

Each opens in a new tab, filled in for Eloxx Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes

Cite this page

Permanent URL: https://mentionfox.com/stakes/eloxx-pharmaceuticals
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Eloxx Pharmaceuticals, Inc. 5%+ holders: 8 at 5% or more, largest Domicilium Capital Partners LLC 19.99%. MentionFox, 2026-09-27. https://mentionfox.com/stakes/eloxx-pharmaceuticals